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(AML) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (ALLO-HCT): BETTER PROGNOSIS THAN SYSTEMIC RELAPSE
Solh, M., Kaufman, D.S., Defor, T., Weisdorf, D.J. University of Minne-
sota, Minneapolis, MN
Introduction: Allo-HCT is considered a curative treatment for
AML; however, leukemia relapse remains the major cause of mortal-
ity after HCT. Extramedullary relapse after HCT for AML is a rare
event and its characteristics and prognosis are less well defined than
systemic relapse. We studied 436 AML allo-HCT patients and ana-
lyzed the characteristics and outcomes of 128 patients who had post-
HCT leukemia relapse; 25 with extramedullary relapse.
Methods:We retrospectively studied all AML patients transplanted
at the University of Minnesota (UM) between 1996 and 2008 who
developed either a bone marrow or extramedullary relapse. Patient
demographics, transplant-related variables and outcomes were pro-
spectively collected and available from the UM transplant data
base. Data regarding site of relapse, therapy and outcome post-
relapse were collected from the patients’ available medical records.
Survival through 6 months post-relapse was estimated using
Kaplan-Meier curves.
Results:Of 128 patients who relapsed post HCT, 25 occured in ex-
tramedullary sites, either isolated (n5 13, group I) or with concom-
ittant marrow relapse (n 5 12, group BM). Relapse sites were bone
(n5 1), central nervous system (n5 6), gastrointestinal (n5 4), lym-
phatic (n5 4), skin (n5 5), genitourinary (n5 1), pulmonary (n5 1)
and soft tissue (n5 3). The median time to relapse was longer in the
extramedullary sites than marrow only (328 vs 168 days). Patients
with extramedullary relapse were more likely to have had preceding
grade II-IV acute GVHD (77% vs 49%; p 5 0.03) or chronic
GVHD (46% vs 15%; p 5 0.02) compared to marrow relapse
only. Among all relapsed patients, chronic GVHD and relapse
within 6months of HCTwere associated with worse overall survival.
However, 6 month survival post relapse was significantly better for
isolated extramedullary relapse (69%) compared to combined
marrow and extramedullary (8%) or marrow relapse alone (27%)
(p \ 0.01). In patients who had isolated extramedullary relapse,
administration of systemic therapy (6 local to relapse site) yielded
better 6 months OS (40-56%) than local (OS 33%) alone.
Conclusion:This study suggests that theremaybedifferent pathogen-
esis for marrow versus extramedullary relapse of AML following allo-
HCT. GVHD and accompanying GVL may better protect marrow
sites, but patients with extramedullary relapse have better outcomes
and have good responses to combined local and systemic therapy.16
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Background: Current concepts of NK alloreactivity are based on
donor/recipient KIR ligand mismatching and on donor KIR geno-
type variants, while little is known about the role of specific activat-
ing KIR genes. Specifically, the importance of the telomeric
KIR2DS1 and KIR3DS1genes, and the centromeric KIR2DS2
gene has not been studied in detail.We tested the hypothesis that in-
dividual donor activating KIR genes would influence the outcome of
AML patients undergoing unrelated allogeneic HCT.
Methods:DonorKIR genotyping was performed for 1228 AMLpa-
tients receiving transplants between 1989 and 2008 from 9/10 or 10/
10 HLA-matched unrelated donors with outcome data provided by
the CIBMTR. HLA genotyping was verified through the NMDP
retrospective typing program. Cox regression was used to examine
the association between donor KIR genotype and HCT outcome.Models were adjusted for age, disease severity, donor/patient gender,
T-cell depletion, conditioning, and HLA mismatch.
Results: 422 donors were KIR2DS1-positive, 429 donors were
KIR3DS1-positive (n 5 355 KIR2DS1pos, KIR3DS1pos), and 630
donors were KIR2DS2-positive. The presence of donor KIR2DS1
was associated with lower relapse [HR 0.76 (0.61-0.96), p 5 0.02],
even after adjusting for presence of KIR2DS2 [adjusted HR: 0.77
(0.61-0.97), p 5 0.02] and presence of donor KIR3DS1, with which
it shares strong positive LD [adjusted HR 0.71 (0.51-0.99), p 5
0.04]. Donor KIR3DS1 was associated with reduced non-relapse
mortality [HR 0.68 (0.50-0.92), p5 0.01] and decreased overall mor-
tality [HR 0.79 (0.63-0.98), p 5 0.03] even after adjusting for donor
KIR2DS1. Interestingly, after adjusting for KIR3DS1, KIR2DS1
positivity had little association with overall mortality [HR 5 1.00
(0.80-1.25, p 5 .98)]. There was no statistically significant associa-
tion of donor KIR2DS2 on survival, relapse, or non-relapse mortal-
ity. Furthermore, the protective effect of donor centromeric KIR
B-haplotype homozygosity on relapse was not statistically significant
[CenBB vs. CenAA, HR 0.8 (0.55-1.15), p 5 0.23].
Conclusion: Individual activating KIR may mediate independent ef-
fects in unrelated allogeneicHCT forAML,withKIR2DS1protecting
from relapse and KIR3DS1 protecting from non-relapse mortality.17
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Objectives:DonorT lymphocytes play a critical role in graft-versus-
host disease (GVHD) and infection prevention in allo-HSCT.CD28
is the primaryT-cell costimulatorymolecule constitutively expressed
onT cells, which transduces a signal that enhances the activation and
proliferation of T cells. Another member of the CD28 family is in-
ducible co-stimulator (ICOS).Althoughnot constitutively expressed,
ICOS is rapidly upregulated onT cells upon activation. CytotoxicT-
lymphocyte antigen 4 (CTLA-4), a homologous molecule of CD28,
is a key factor in regulating andmaintaining self-tolerance, providing
a negative signal toT cells.The aimof this studywas to analyze donor
and recipientT-cell costimulatorymolecule gene polymorphisms as-
sociated with CMV infection within 100 days after HSCT.
Methods:We analyzed 5 single nucleotide polymorphisms (SNPs):
CD28 -594(A/G), ICOS -693(G/A) and CTLA-4 -1722(A/G), 149
(A/G) and CT60 (A/G) in a cohort of 116 pairs of recipients and un-
related donors and a second cohort of 87 pairs of recipients and
HLA-identical sibling donors.
Results: (1) All patients and donors are CMV seropositive before
HSCT (only one donor fromTaiwan is CMV seronegative). 117 pa-
tients (57.6%) had experienced early CMV infection with a median
onset of 26 days (range2-64) after HSCT. 23% of 117 patients devel-
oped infection during granulocytopenia and 77% after neutrophil
recovery. 92.3% of 117 patients developed CMV positive antigene-
mia without disease, only 9 patients developed CMV disease (7 pa-
tients with pneumonia and 2 patients with enteritis). (2) Patients
receiving stem cells from a donor with CTLA-4 CT60 AA genotype
had a higher incidence of early CMV infection than those with AG/
GG genotypes in both the unrelated and sibling cohorts. (3) Multi-
variate analysis identified four risk factors for early CMV infection:
patients with CMV reactivation pre-HSCT (RR: 0.668, 95%CI:
0.454-0.983, P 5 0.041), unrelated donor (RR: 0.528, 95%CI:
0.349-0.8, P 5 0.003), patients experiencing aGVHD (RR: 1.606,
95%CI: 1.074-2.403, P 5 0.021) and donors with CTLA-4 CT60
AA genotype (RR: 2.369, 95%CI: 1.461-3.841, P\ 0.001).
Conclusion: Although CMV disease has been reduced in the era of
antiviral prophylaxis and preemptive therapy, our findings suggest
the incidence of CMV infection remains high and provide the first
report of relationship between T-cell costimulatory molecule gene
polymorphic features to the risk of early CMV infection.
